OL 101
Alternative Names: OL-101Latest Information Update: 20 Jan 2025
Price :
$50 *
At a glance
- Originator Overland Pharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 13 Nov 2024 Pharmacodynamics data from a preclinical study in Multile myeloma released by Overland Therapeutics (Overland Therapeutics pipeline, November 2024)
- 23 Oct 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT06644118)
- 23 Oct 2024 Preclinical trials in Multiple myeloma in China (IV) prior to October 2024